Basilea Pharmaceutica AG (0QNA.L) Stock Price
CHF47.05 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
4 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Basilea Pharmaceutica AG, AI stock picks, stock alerts and much more.
0QNA.L AI Stock Analysis
AI stock analysis for 0QNA.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Basilea Pharmaceutica AG (0QNA.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Basilea Pharmaceutica AG (0QNA.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Basilea Pharmaceutica AG (0QNA.L), currently trading at CHF47.05, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0QNA.L
-
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
-
Symbol
0QNA.L
-
Market
LSE
-
Industry
Medical - Pharmaceuticals
-
Market Cap
578.1M
Similar Stocks
 |
Vertex Pharmaceuticals Incorporated 0QZU.L |
$398.5 0.5% |
7 |
 |
Neurocrine Biosciences 0K6R.L |
$136.1 1.2% |
7 |
 |
Emergent BioSolutions Inc. 0IGA.L |
$9.46 2.9% |
4 |
 |
Abeona Therapeutics Inc. 0H7R.L |
$7.25 1.7% |
5 |
 |
Walgreens Boots Alliance 0LSZ.L |
$12.17 0.5% |
5 |
News
0QNA.L Alternative Data
Web Traffic
Basilea Pharmaceutica AG receives an estimated 13145 monthly visitors to basilea.com.
-
Web Traffic
13145
-
Change from Previous Month
58.6%
-
3 Month Change
110.8%
-
YoY Change
110.8%
Job Postings
Basilea Pharmaceutica AG currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
Basilea Pharmaceutica AG has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
19,914 are following Basilea Pharmaceutica AG on LinkedIn, up by 1.9% over the last month.
-
LinkedIn Followers
19914
-
Daily Change
1.9%
-
1 Month Change
1.9%
-
3 Month Change
4.8%
-
YoY Change
4.8%
LinkedIn Employees
According to LinkedIn, Basilea Pharmaceutica AG has 232 employees, down by -0.9% over the last month.
-
LinkedIn Employees
232
-
Daily Change
0.9%
-
1 Month Change
0.9%
-
3 Month Change
2.2%
-
YoY Change
2.2%
Business Outlook
According to employee reviews, the business outlook among employees at Basilea Pharmaceutica AG is 38 out of 100 (bearish).
-
Business Outlook
38
-
Change from Previous Month
0%
-
3 Month Change
0%
News Mentions
Basilea Pharmaceutica AG was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
0QNA.L Financials
0QNA.L Key Metrics
-
Total Revenue
CHF132.3M
-
Net Income
CHF56.9M
-
Earnings per Share
CHF4.2
-
Free cash flow
CHF55.2M
-
EBITDA
CHF53M
-
EBITDA Ratio
0.400571
-
Total Assets
CHF257.8M
0QNA.L 2-year Revenue & Income
0QNA.L 2-year Free Cash Flow
0QNA.L Technicals
0QNA.L SMA
0QNA.L RSI
FAQ
What's the current price of Basilea Pharmaceutica AG (0QNA.L) Stock?
The price of an Basilea Pharmaceutica AG (0QNA.L) share is CHF47.05.
What's the market cap of Basilea Pharmaceutica AG?
The current market cap of Basilea Pharmaceutica AG is 578.1M.
Should I buy or sell 0QNA.L?
Basilea Pharmaceutica AG shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Basilea Pharmaceutica AG is better viewed as a hold or accumulate position while waiting for further developments.
Is Basilea Pharmaceutica AG a good investment?
The current analysis of Basilea Pharmaceutica AG's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Basilea Pharmaceutica AG's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Basilea Pharmaceutica AG (0QNA.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Basilea Pharmaceutica AG stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Basilea Pharmaceutica AG (0QNA.L) that investors often compare it to?
Basilea Pharmaceutica AG (0QNA.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.
What is the forecast for Basilea Pharmaceutica AG's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Basilea Pharmaceutica AG's stock price to be around CHF47.14 in 2026. Starting from the current price of CHF47.05, this represents a 0.2% change in price, indicating a neutral outlook for the stock.
How to buy Basilea Pharmaceutica AG (0QNA.L) Stock?
Basilea Pharmaceutica AG stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Basilea Pharmaceutica AG shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.